MDX-210: Began Phase II trial

Medarex Inc. (MEDX), Princeton, N.J. Product: MDX-210 bispecific antibody targeting the Her-2/neu protein on cancer cell surfaces, and a trigger antibody that attaches to killer cells of the immune sy...